Australia Opens Consultation on Cannabis Cultivation Rules Ahead of 2027 Sunset

Consultation Targets Licensing Framework Set to Expire

The TGA's consultation addresses the Narcotic Drugs Act 1967 licensing scheme, which governs all legal cultivation and manufacturing of cannabis for medicinal and research purposes in Australia. Under current law, the licensing framework sunsets on July 1, 2027, unless Parliament extends or replaces it. The TGA hasn't disclosed whether it'll recommend extension, modification, or a new regulatory structure.

A strict reading of the Narcotic Drugs Act 1967 shows the sunset provision applies to the entire Part governing cannabis licenses, not just individual license terms. This means the legal authority to issue new cultivation licenses expires unless Parliament acts before mid-2027.

Key Issues Under Review

The TGA identified four priority areas for stakeholder comment: license application requirements, ongoing compliance obligations, security and quality standards, and reporting frameworks. The consultation paper doesn't propose specific rule changes. Instead, it asks whether current requirements remain fit for purpose.

Specific consultation questions include:

• Whether the current two-tier licensing structure (cultivation licenses and manufacturing licenses) should be consolidated or separated further
• Whether security requirements for cannabis cultivation facilities align with comparable pharmaceutical manufacturing standards
• Whether Good Manufacturing Practice (GMP) standards should apply uniformly to all cannabis products or vary by product type
• Whether the current reporting frequency (quarterly) imposes excessive compliance costs on smaller license holders

Australia currently has 87 active medicinal cannabis licenses. That's 34 cultivation licenses, 41 manufacturing licenses, and 12 combined licenses.

Compliance Cost Data Shapes Regulatory Review

The consultation paper cites TGA data showing the average annual compliance cost per license holder is AU$127,000, with smaller operators reporting costs exceeding 15% of gross revenue. The TGA asked whether alternative compliance models—such as risk-based auditing or third-party certification—could reduce costs without compromising product safety.

The current framework was designed in 2016 when Australia had fewer than 10 license holders; scaling the same requirements to nearly 90 operators has created administrative friction the TGA now seeks to address.

For full background on Australia's medicinal cannabis framework, see the CannIntel topic hub on Australia Cannabis Regulation.

What Operators Should Watch

The consultation closes August 15, 2026, with the TGA expected to publish a decision paper in Q4 2026. If the TGA recommends extending the current framework with modifications, draft amendments would likely be tabled in Parliament by March 2027 to avoid a regulatory gap.

If Parliament doesn't act by July 1, 2027, the TGA would lose statutory authority to issue or renew cannabis licenses. That freezes the legal supply chain. No Australian regulator has indicated contingency plans for such a scenario.

Operators should submit written comments by the August deadline. The TGA will also hold two virtual stakeholder sessions in July 2026, though dates haven't been announced.